Impact of funding on biomedical research: a retrospective cohort study by Decullier, Evelyne & Chapuis, François
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Public Health
Open Access Research article
Impact of funding on biomedical research: a retrospective cohort 
study
Evelyne Decullier1 and François Chapuis*2
Address: 1Clinical Epidemiology Unit; DIM-Hospices Civils de Lyon, Lyon, France and 2Claude Bernard University Lyon 1; RECIF- Hospices Civils 
de Lyon, 162 av Lacassagne, 69424 Lyon cedex 03, France
Email: Evelyne Decullier - evelyne.decullier@chu-lyon.fr; François Chapuis* - francois.chapuis@chu-lyon.fr
* Corresponding author    
Abstract
Background: Public funding is aimed at facilitating the initiation, completion and publication of
research study protocols. However, no evaluation is made to investigate the impact of grant
success on the conduct of biomedical research. It is therefore of great interest to compare the fate
of funded protocols versus not funded: Are they initiated? Are they completed? Did the results
confirm the hypothesis? Were they published? The objective was to investigate the fate of
protocols submitted for funding, whether they were funded or not.
Methods: Retrospective cohort study of protocols submitted for funding to the Greater Lyon
regional scientific committee in 1997. Initial characteristics of protocols (design, study size,
investigator status) were abstracted from archives, and follow-up characteristics (initiation,
completion and publication) from a mailed questionnaire to the principal investigators.
Results: Among the 142 submitted protocols, follow-up information was available for 114 (80%).
As a whole, 38% of studies were funded by the Greater Lyon research committee. The rate of
initiation varied from 62% for studies with no acknowledged funding to 100% for studies with both
committee and other simultaneous funding. When initiated, the rate of completion was 62% for
studies with at least one funding and 40% for studies without acknowledged funding. When
completed, publication was reached for 77% of studies with either committee or external funding,
for 58% of studies without acknowledged funding and for 37% of studies with both committee and
external funding.
Conclusion: Some protocols submitted for funding were initiated and completed without any
funding declared. To our understanding this mean that not all protocols submitted really needed
funding and also that health care facilities are unaware that they implicitly financially support and
pay for biomedical research.
Background
Public total expenditures in biomedical research have
grown in recent years[1].
In the USA, the National Institutes for Health's (NIH)
total appropriation rose to $28 billion in 2004 [2]. In
France, the cost of public clinical research conducted in
teaching hospitals and cancer centres was estimated at
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116 million euros in 2000 [3], 129 million euros in 2001
(+11% in one year) [4] and 154 million euros in 2002
(+32% in two years) [5].
Despite previous increases in public budget for clinical
research, competition for obtaining funds is therefore
rough since the success rates for grants remained fairly the
same [2] and the competition will become even tougher
in a context of public financial pressures to limit the
budget for biomedical research [2,6,7].
It is expected that all research funded will lead to publica-
tion and this was explicitly mentioned in the law that set-
tled the French National funding scheme[8]. In this
perspective, a study on 1996 NIH grants found that each
grant lead to 7.6 manuscripts [9]. Moreover, the NIH
requested in 2005 that all publications resulting from
NIH-funded research be deposited in PubMed Central
[10].
The French Ministry of Health has also planned regular
assessment of its national funding scheme, and four eval-
uations have been conducted at the national level in
France (on protocols funded in 1993 [11], 1994 [12],
1995 [13], and 1996 [14]). In the USA, all protocols
funded by the NIH in 1979 were evaluated to investigate
publication bias, but the fate of the studies was not stud-
ied [15].
None of these evaluations investigated if the funded pro-
tocols were also submitted to complementary fundings,
and if these submissions were successful.
Public funding is aimed at facilitating the initiation, com-
pletion and publication of protocols. However, both
French and NIH evaluations were limited to funded
research; this design hampers to investigate the impact of
obtaining a funding on the conduct of biomedical
research.
It is therefore of great interest to compare the fate (initia-
tion, completion and publication) of funded protocols
versus not funded, as well as to compare the fate accord-
ing to type of funding. Our objective was to follow all pro-
tocols submitted for funding to the regional scientific
committee of Greater Lyon in 1997 and to investigate
their fate according to the obtaining of funding: are these
protocols funded elsewhere? Are they initiated? Are they
completed? Did the results confirm the hypothesis? Do
investigators consider the study results as important?
Were the results published? Our hypothesis was that
absence of acknowledged funding does not hamper
implementation nor publication.
Methods
All biomedical research protocols submitted for funding
to a French regional scientific research committee (Greater
Lyon, France) in 1997 were included.
Data collection
All protocols submitted are archived by the regional scien-
tific committee. Data on initial characteristics (scope,
duration, and design), funding results (yes, no) and
amount (converted into 1997 euros) were collected by the
same person (ED) to ensure homogeneity. To confirm
data extraction, main data of interest were reviewed by FC.
When variables were ambiguous or not clearly stated in
protocols, data were revised by both FC and ED to reach
an agreement. To obtain follow-up characteristics (initia-
tion, completion, publication), a mailed questionnaire
was sent to the principal investigator of each submitted
protocol. The principal investigators were contacted up to
three times to obtain the completed questionnaire in
2003.
Definitions
Committee funding: two kinds of regional scientific com-
mittee fundings were considered:
- National funding scheme for clinical research: In 1992,
the French Ministry of Health launched a national fund-
ing scheme aiming to support biomedical research in
French hospitals [8].
- Lyon hospital system's internal funding schemes include
special funding for research assistants, young researchers,
registered nurses, support for clinical research protected
time and support for clinical research facilities.
External funding: investigators had to declare if the proto-
col had been submitted to other funding schemes, and if
so, if they succeeded.
To avoid confusion between different sources of funding,
protocols funded after evaluation by the regional scien-
tific committee were labelled "committee-funded proto-
cols" (and "not committee-funded protocols") and
protocols funded after other applications were labelled
"externally funded protocols" (and "not externally
funded").
Legal and methodological definitions used are provided in
table 1[16,17].
Fate: specific endpoints of a research protocol (initiation,
completion and publication).
Rating of study results: Investigators were asked to self-rate
the importance of their study (Table 1).BMC Public Health 2006, 6:165 http://www.biomedcentral.com/1471-2458/6/165
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The direction of results was categorized as follows: protocol
results were considered as "important" if the rating of the
importance of the study results by the investigator was
greater than 5/10 (5 being the mean on a 1 to 10 scale),
and results were considered as "unimportant" when this
rating was lower or equal to 5.
Scientific publication, oral presentation and grey litera-
ture [18] were based on investigators' declaration.
Publication bias is defined as the tendency on the parts of
investigators, editors, and others to favour publication of
research with positive results compared to research with
null or negative results [19]. As a parallel, oral presenta-
tion bias is the tendency, on the parts of researchers as
well as reviewers of scientific boards of meetings, to sub-
mit or accept significant results for oral presentation.
Ethical considerations
This study was conducted according to the French law on
epidemiologic and descriptive studies [16]. Data were col-
lected anonymously on each investigator and no consent
was required since no individual information was
retrieved.
Statistics
We obtained frequency distributions for all variables
(means and percentages). When assessment of association
was needed, χ2 tests were used for qualitative variables.
We restricted analysis of publication to the cohort of com-
pleted studies. We excluded studies from the analysis
when the rating of results was not provided by the inves-
tigator. To obtain an odds ratio for publication bias and
oral presentation bias, we introduced these variables in a
univariate logistic regression model [20].
SAS software was used for all analyses. We considered
associations to be statistically significant when p values
were less than 0.05.
Results
During the year 1997, 144 protocols were submitted for
funding to the Greater Lyon regional scientific committee:
63 (44%) to the national funding scheme and 81 (56%)
to the Lyon Hospital system's internal funding schemes.
Two protocols were only "intention letter" with no com-
plete protocol available and were therefore not included.
A questionnaire was sent to the principal investigator of
the 142 protocols included and an answer was received
for 114 (80%): five investigators were not located, 18 did
Table 1: Definitions
Legal definitions
Huriet-Serusclat Act French law [16] passed in 1988 and modified in 2004, providing a framework for biomedical 
research protocols involving human beings. This law set up a national system of research ethics 
committees. Every protocol involving humans in France must be approved by one of the French 
research ethics committees.
Intervention requiring ethics committee approval according to the French law [16] and to the International Committee for Harmonization- Good 
Clinical Practices guidelines [17], each intervention made on a human subject requires prior 
approval of a research ethics committee. This approval is based on the evaluation of protocols, 
data forms, informed consent and administrative requirements.
Methodological definitions
Study design Clinical
•Descriptive: description of a cohort or a case series with no intervention
•Experimental: with an intervention on humans and with a control group
•Analytical: a hypothesis is tested on a cohort or in a case-control study
Not clinical: protocol for which the subject of research is not a human being (such as protocol 
on tumour characterisation, protocols on molecules, proteins, etc.).
Study initiation and completion Investigators were asked to classify their study as initiated/not initiated and as completed/not 
completed and the reason for non-completion (on-going/stopped)
Rating of study results Investigators were asked to rate the importance of their study results from 1 to 10, 1 being 
"not important", 10 being "very important".
Scientific publication Investigators had to declare if study results were published or not published as a scientific paper
Oral presentation Investigators had to declare if study results were presented orally or not (with no details on 
peer-review, or scope of the meeting: regional, national or international)
Grey literature Literature not generally accessible through libraries (internal reports, thesis, abstracts, posters)BMC Public Health 2006, 6:165 http://www.biomedcentral.com/1471-2458/6/165
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not answer and five others answered that they did not
wish to complete the questionnaire. The association
between funding status and response from the investiga-
tor was tested and did not reveal any response bias.
Initial characteristics of the 142 protocols
Initial files were missing for five (4%) protocols. Half of
the protocols involved human beings and had therefore
to be evaluated by a research ethics committee as well.
(Table 2). The design was randomised controlled for 20
(14%).
Most protocols were conducted in France only (n = 128;
90%) and one-half of them in a single centre.
The expected number of patients was provided for 100
(74%) protocols (minimum: 5 patients; maximum:
80,000; median: 100), not applicable for 21 (14%), no
Table 2: Initial characteristics of the 142 protocols
n%
Field of investigation: Epidemiology 27 19
Diagnostic acts 23 16
Laboratory-based 17 12
Physiology 14 10
Drug evaluation 12 8
Genetics 11 8
Psychology-sociology 6 4
Radiotherapy 5 4
Economic evaluations 3 2
Sport medicine 2 1
Surgical strategies 2 1
Quality of care 2 1
Others 13 9
Investigator status: Hospital consultant 65 46
Professor/hospital consultant 54 38
Reader/hospital consultant 12 8
Other 6 4
Study design Descriptive 45 32
Experimental 35 25
Analytical 27 19
Not clinical 28 20
Not available 2 1
Intervention requiring ethics committee approval Yes 59 42
No 75 53
Not available 3 2
Place of research Hospital 88 62
Laboratory 19 13
Multiple 25 18
Other places 5 4
Centres Single centre 70 51
Multicentric-national 58 42
Multicentric-international 7 5
Not available 2 1
Overall Total 137 96
Missing files 5 4
Total 142 100BMC Public Health 2006, 6:165 http://www.biomedcentral.com/1471-2458/6/165
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estimations were calculated for 16 (12%), and were miss-
ing for five (4%).
An expected duration in months was provided for 96
(68%) protocols (minimum: 6 months, maximum: 84
and median: 24).
Funding
Among the 142 protocols included, 54 were committee-
funded (38%): 26 (42%) were submitted to the national
funding scheme and 28 (35%) for HCL-internal applica-
tions. In 1997, the amount of funding after evaluation by
the Lyon regional scientific committee was 3,139,000
euros (86% of which came from the national funding
scheme). The funding granted ranged from 3,050 euros
for a diagnostic strategy protocol to 274,400 euros for two
regional studies, with a median of 34,200 euros.
Other funding applications
In the subset of protocols for which the investigator
responded to the questionnaire (114/142), 46 (40%)
were committee-funded.
Simultaneous submissions for other grants or funding
were declared by 38 investigators (33%; 14/46 commit-
tee-funded protocols and 24/68 that were not committee-
funded). At least two other submissions for funding were
declared for 34% (13/38) and at least three for 13% (5/
38). These submissions were addressed to private grant
applications in 18% of cases (7/38), to other public
schemes (66%; 25/38) including specific associations
such as cancer associations. Another 11% (4/38) declared
that they decided to use previous public funding already
available from another study and 5% (2/38) did not pro-
vide any answer.
Overall, simultaneous submissions for external funding
were successful for 30 (79%), and for 6 out of 7 in case of
submission to private companies. Only ten (9%) investi-
gators declared that they obtained both committee-fund-
ing and external-funding (Figure 1).
Among the 6 private fundings, 4 did not obtained com-
mittee-funding. Considering all funding sources globally,
39% of investigators considered that all their study
expenses were covered (n = 45), 26% that expenses were
only partially covered (n = 30) and 10% declared that the
funding was not sufficient at all (n = 11). Another 28 did
not answer this question (25%).
Fate
The fate of submitted protocols according to funding sta-
tus is presented on Figure 1. Among the 114 answers
received from investigators of submitted protocols, 93
(82%) of the studies were initiated. A total of 30 (62%)
studies that were not funded were actually initiated. When
both committee funding and external funding were
obtained, 100% of the studies were initiated (p < 0.001).
When there was at least one private funding source
involved, the initiation rate was 86% and 81% otherwise
(NS). On the other hand, the main reason provided by
investigators to explain non-initiation of 21 protocols was
absence of funding (n = 17; 81%).
Among the initiated studies, completion was declared for
8/10 (80%) committee-funded and externally funded
studies, and for 12/30 (40%) studies with no funding.
When there was at least one private funding source
involved, the completion rate was 67% and 54% other-
wise (NS). Most studies were stopped due to subject
recruitment difficulties (31%), technical (methodology,
time, etc) difficulties (31%) or funding difficulties (15%).
Publication rates varied from 37% for studies with both
committee funding and external funding to 90% for stud-
ies with external funding only (p = 0.11).
When there was at least one private funding source
involved the publication rate was 75% (3/4) and 66%
(31/47) otherwise (NS).
Randomised controlled trials fate
An answer from investigator was obtained for 75% (15/
20) of randomised clinical trials. The initiation and the
completion rates were respectively 93% and 100% but a
publication was made only for 33% (n = 5).
Rating of study results
Investigators of initiated studies were asked to rate the
importance of their study results. An answer was obtained
for 74 of the 93 initiated studies. The study was still on-
going for half of the non-responses. The overall mean
ranking was 6.5/10 (Table 3). For the 47 completed stud-
ies, the mean rating was 6.7. The rating was greater than
5/10 ("important result") for 37 (79%).
Results were considered as being "important" for all pro-
tocols in which there was at least one private funding
source involved (rating of 7/10 for the 4 protocols),
Publication bias
For publication bias analysis on 51 completed studies, we
had to exclude four studies for which the rating of study
results was not available (Table 4). Among the 47 remain-
ing protocols, 17 (36%) had not been published. The
main reason explaining non-publication at the time of
our study was that the paper was currently being prepared,
written or submitted (n = 11; 65%). Two investigators
declared that they had no time to write (12%), one thatBMC Public Health 2006, 6:165 http://www.biomedcentral.com/1471-2458/6/165
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the results were not interesting enough (6%) and three
did not provide an explanation (17%).
The odds ratio for publication of important results versus
unimportant results was 1.58 (95% CI: 0.37–6.71).
Oral presentation bias
Oral presentations were made for 39 (83%) of the 47 doc-
umented and completed studies. When results were
deemed unimportant, 2/10 (20%) resulted in neither
publication nor oral presentation (Table 4). Moreover,
externally funded protocols had the lowest rate of oral
presentation only and the highest rate for publication
only. The odds ratio for oral presentation of important
versus unimportant results was 1.29 (95% CI: 0.22–7.65).
Dissemination of results
Fifty-one studies were completed (whether or not they
were rated by the investigators) and 34 lead to scientific
publication of which 50% resulted in multiple publica-
tions. Among the 17 studies not leading to scientific pub-
lication, there was no dissemination at all for four, and
Fate of protocols submitted to a regional scientific committee Figure 1
Fate of protocols submitted to a regional scientific committee.
142 protocols submitted to Lyon biomedical research committee
Protocols available for analysis (n= 114, 80%)
No follow-up information
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grey literature was produced for the remaining 13 studies.
Grey literature comprised 46% abstracts only (n = 6), 15%
internal reports only (n = 2), 15% an internal report and
an abstract (n = 2), 15% an academic doctoral thesis only
(n = 2) and 8% a doctoral thesis, an internal report and an
abstract (n = 1).
Discussion
Our hypothesis was that absence of acknowledged fund-
ing does not hamper implementation nor publication.
Overall, 82% of protocols submitted for funding to the
Greater Lyon regional scientific committee and for which
an answer of the investigator was obtained were initiated,
half of these initiated studies were completed 6 years later.
Even when not funded, 30 studies out of 48 were initiated
(62%), confirming our main hypothesis. Moreover, we
highlighted a tendency for publication bias as well as oral
presentation bias, although this was not statistically sig-
nificant for study power reason.
Our study was the first to include protocols submitted on
a comprehensive 1-year period to different types of public
funding and was also the first to provide a follow-up of
protocols that were not funded, whether they obtained
other grants (e.g. private funding) or were conducted
without any funding at all. It was based on only one
regional scientific committee. However, this is the only
regional committee not specialized and in charge of all
health care facilities from general practice to highly spe-
cialised hospitals, i.e., cancer facilities, psychiatry and
high-level tertiary teaching hospitals. The year 1997 was
chosen to ensure enough time to conduct and complete a
study and to publish the results
Some variables definitions, such as study design, were a
source of problems when we extracted data from the pro-
tocols. This was partly due to imprecise definitions gener-
ally used in the literature, but also to the sometimes poor
quality of submitted protocols. The variable named "p-
value of the statistical test" was not used in the analysis
since it was insufficiently documented by the investiga-
tors: in some cases, no statistical test could be performed,
e.g. for descriptive non-comparative designs, but in other
cases the data were truly missing. For these reasons, we
relied on study results rated by the investigator over 5 (on
a scale of 10). This threshold was chosen in order to
ensure the minimal positive feeling of the investigator
about his own study.
Self-rating by investigators is a subjective indicator, but it
is very relevant since the choice to publish results is not
always based on statistical significance but also on a sub-
jective perception of the importance of the study results.
The only article published on this topic provided informa-
tion on protocols funded by the NIH [15]. The results of a
Table 3: Investigator rating of study importance according to protocol status (on a 1 to 10 scale)
Protocol status n Median Minimum Maximum Mean
Stopped 9 5.0 1.0 7.5 4.4
On-going 18 7.0 3.0 10.0 7.0
Completed 47 7.0 3.0 9.0 6.7
Overall 74 7.0 1.0 10.0 6.5
Table 4: Rating of study results and funding status according to oral presentation and scientific publication
Overall Results Funding status
Positive
(rating > 5)*
Negative
(rating ≤ 5)*
None Committee-
funded only
Externally-
funded only
Both
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Published only 4 (8) 4 (11) 0 (0) 2 (17) 0 (0) 2 (20) 0 (0)
Orally presented and published 28 (59) 22 (60) 6 (60) 5 (42) 13 (72) 7 (70) 3 (43)
Orally presented only 11 (23) 9 (24) 2 (20) 2 (17) 4 (22) 1 (10) 4 (57)
Not published, not orally presented 4 (8) 2 (5) 2 (20) 3 (25) 1 (6) 0 (0) 0 (0)
47 (100) 37 (100) 10 (100) 12 (100) 18 (100) 10 (100) 7 (100)
* Investigators were asked to rate the importance of their study results from 1 to 10, 1 being "not important", 10 being "very important".BMC Public Health 2006, 6:165 http://www.biomedcentral.com/1471-2458/6/165
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follow-up of NIH-funded protocols were presented, but
only funded and implemented protocols were included,
we believe our inclusion criteria are closer to the reality as
well as to the questioning of a scientific committee mem-
ber. Other scientific articles, including some meta-analy-
ses, although not dedicated to the subject, may also give
some information on protocols' fate.
Reports on the French national funding scheme have also
been made public but were not published and restricted
to funded protocols and to only one source of public
funding [11-14].
Our completion rate was 55% at 5 years, to be compared
with 68% nine years later for the NIH funded protocols
and at least 80% for the four French previously mentioned
unpublished reports [11-14]. However in our study there
were more still on-going protocols than in these reports
(23% vs. 11%).
Publication rates [15,21-25], seem to differ dramatically
between authors. This difference might be due to the com-
position of the protocol cohorts. In our literature analysis,
we extracted from each paper the publication rate and the
percentage of protocols funded by pharmaceutical firms.
In these papers, publication rates never reach 100% but
differ according to the status of the funder: when the per-
centage of protocols funded by pharmaceutical firms was
greater than 60%, the publication rate was less than 55%.
Otherwise, the publication rate was greater than 65%.
In our study, publication rate was higher for private fund-
ings, which is not consistent with research on this subject
[15,21-26]. This could be explained by the fact that proto-
cols submitted for fundings from both public and private
sectors are different from those which only targeted pri-
vate sector. Our study was not designed to answer this
question, moreover the small number of completed pro-
tocols with private fundings did not allow to see if this
research was more likely to produce significant results as
shown in other papers[26,27].
Most funded protocols were descriptive, reflecting the
general situation in the 1990s when public funding was
mostly aimed at the description of clinical or epidemio-
logical situations. Today, one could find more funding for
interventional/experimental protocols, and this could be
checked in few years when the current ongoing protocols
will have been completed and published.
Since many protocols submitted for funding were initi-
ated without any funding declared, does this mean that
not all protocols submitted really needed funding? Or
does this mean that health care facilities are unaware that
they financially support and pay for biomedical research?
To our understanding, both situations occur.
Conclusion
More attention should be given to the follow-up of proto-
cols submitted to grant application, this could be eased by
the creation of local/national registries. Such registries
could also help to describe the total number of applica-
tions and the total amount of money allocated per proto-
col, and should also be used to study the follow-up and
the fate of submitted protocols, whether they are funded
or not.
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